Search: onr:"swepub:oai:DiVA.org:uu-197072" >
New autoimmune dise...
New autoimmune diseases after cord blood transplantation : a retrospective study of EUROCORD and the Autoimmune Disease Working Party of the European Group for Blood and Marrow Transplantation
-
Daikeler, Thomas (author)
-
Labopin, Myriam (author)
-
Ruggeri, Annalisa (author)
-
show more...
-
Crotta, Alessandro (author)
-
Abinun, Mario (author)
-
Hussein, Ayad Ahmed (author)
-
- Carlson, Kristina (author)
- Uppsala universitet,Hematologi
-
Cornillon, Jerome (author)
-
Diez-Martin, Jose L. (author)
-
Gandemer, Virginie (author)
-
Faraci, Maura (author)
-
Lindemans, Caroline (author)
-
O'Meara, Anne (author)
-
Mialou, Valerie (author)
-
Renard, Marleen (author)
-
Sedlacek, Petr (author)
-
Sirvent, Anne (author)
-
Socie, Gerard (author)
-
Sora, Federica (author)
-
Varotto, Stefania (author)
-
Sanz, Jaime (author)
-
Voswinkel, Jan (author)
-
Vora, Ajay (author)
-
Yesilipek, M. Akif (author)
-
Herr, Andree-Laure (author)
-
Gluckman, Eliane (author)
-
Farge, Dominique (author)
-
Rocha, Vanderson (author)
-
show less...
-
(creator_code:org_t)
- American Society of Hematology, 2013
- 2013
- English.
-
In: Blood. - : American Society of Hematology. - 0006-4971 .- 1528-0020. ; 121:6, s. 1059-1064
- Related links:
-
https://ashpublicati...
-
show more...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- To describe the incidence, risk factors, and treatment of autoimmune diseases (ADs) occurring after cord blood transplantation (CBT), we analyzed both CBT recipients reported to EUROCORD who had developed at least 1 new AD and those who had not. Fifty-two of 726 reported patients developed at least 1 AD within 212 days (range, 27-4267) after CBT. Cumulative incidence of ADs after CBT was 5.0% +/- 1% at 1 year and 6.6% +/- 1% at 5 years. Patients developing ADs were younger and had more nonmalignant diseases (P < .001). ADs target hematopoietic (autoimmune hemolytic anemia, n = 20; Evans syndrome, n = 9; autoimmune thrombocytopenia, n = 11; and immune neutropenia, n = 1) and other tissues (thyroiditis, n = 3; psoriasis, n = 2; Graves disease, n = 1; membranous glomerulonephritis, n = 2; rheumatoid arthritis, n = 1; ulcerative colitis, n = 1; and systemic lupus erythematosus, n = 1). Four patients developed 2 ADs (3 cases of immune thrombocytopenia followed by autoimmune hemolytic anemia and 1 Evans syndrome with rheumatoid arthritis). By multivariate analysis, the main risk factor for developing an AD was nonmalignant disease as an indication for CBT (P = .0001). Hematologic ADs were most often treated with steroids, rituximab, and cyclosporine. With a median follow-up of 26 months (range, 2-91), 6 of 52 patients died as a consequence of ADs. We conclude that CBT may be followed by potentially life-threatening, mainly hematologic ADs.
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
-
Blood
(Search for host publication in LIBRIS)
To the university's database
- By the author/editor
-
Daikeler, Thomas
-
Labopin, Myriam
-
Ruggeri, Annalis ...
-
Crotta, Alessand ...
-
Abinun, Mario
-
Hussein, Ayad Ah ...
-
show more...
-
Carlson, Kristin ...
-
Cornillon, Jerom ...
-
Diez-Martin, Jos ...
-
Gandemer, Virgin ...
-
Faraci, Maura
-
Lindemans, Carol ...
-
O'Meara, Anne
-
Mialou, Valerie
-
Renard, Marleen
-
Sedlacek, Petr
-
Sirvent, Anne
-
Socie, Gerard
-
Sora, Federica
-
Varotto, Stefani ...
-
Sanz, Jaime
-
Voswinkel, Jan
-
Vora, Ajay
-
Yesilipek, M. Ak ...
-
Herr, Andree-Lau ...
-
Gluckman, Eliane
-
Farge, Dominique
-
Rocha, Vanderson
-
show less...
- Articles in the publication
-
Blood
- By the university
-
Uppsala University